Phase 2 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are male or female, of any race, and are over 18 years old.
- You have been diagnosed with a condition called RIS (Radiologically Isolated Syndrome — an incidental finding on brain scans that may be related to MS) within the last five years.
- You are willing and able to sign a consent form agreeing to take part.
Who may not be able to join:
- You are currently pregnant or breastfeeding.
- You have used immune-suppressing or immune-modifying medications in the last five years (occasional use of corticosteroids/steroids may be acceptable — confirm with trial site).
- You have a serious or unstable health condition that could make it unsafe to participate, such as heart, lung, liver, kidney, or metabolic problems, certain infections, cancer, or immune system disorders (confirm with trial site).
- You have a mental or physical health condition that might affect your ability to give consent or fully complete the trial, or your doctor feels you are otherwise not a suitable candidate.
- You are unable to have an MRI scan.
- You are currently receiving radiotherapy.
- You have a known allergy to any ingredient in the vaccine being studied.
- You have previously had a bone marrow stem cell transplant or an organ transplant.
- You have received any other vaccine in the four weeks before joining the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Giovanni Ristori, S.Andrea Hospital, University of Roma La Sapienza
Phone: +390633776044
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
cumulative number of CUAL (new gadolinium T1-weighted lesions and non-enhancing new and newly enlarging T2-weighted lesions) on MRI scans over 1 year.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.